In this episode, I'm breaking down two peptides that I think are about to blow up: mazdutide and survodutide. Both are GLP-1 and glucagon dual agonists. Think of them like retatrutide minus the GIP component. And that glucagon piece is what makes them special.

I go through the trial data for both compounds. We're talking up to 21% weight loss with mazdutide and 80% liver fat reduction. Survodutide earned FDA breakthrough therapy designation for MASH based on a 62% resolution rate. These are serious numbers.

Here's what most people don't realize. These two peptides are NOT the same. Mazdutide runs close to a 50/50 split between GLP-1 and glucagon agonism. Survodutide is roughly 8 to 1 in favor of GLP-1. That changes everything about tolerability, appetite suppression, and how much metabolic burn you're actually getting.

I also cover practical use cases. Cycling off reta without losing momentum. Choosing between the two based on whether you need more appetite control or more energy expenditure. Dosing guidance for people just starting out. And why escalating too fast is still the number one mistake people make with GLP-1 peptides.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app